7 research outputs found
A 12-Month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment In Terms Of Patient Satisfaction In Relapsing Remitting Multiple Sclerosis Patients Fine Trial
Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. Methods: Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life. Results: Forty-two patients (62% male; mean age: 35.7 +/- 9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study 44.7 +/- 9.9) were significantly higher than those at baseline [32.0 +/- 9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drugrelated. Conclusion: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.Wo
A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial
Introduction: To assess satisfaction and quality of life in patients
with relapsing-remitting multiple sclerosis (RRMS) who were receiving
fingolimod (0.5 mg/day) for 12 months as a second-line treatment after
switching from injectable agents.
Methods: Patients aged 18-65 years with RRMS who fulfilled the
eligibility criteria were enrolled from 16 centers throughout Turkey.
Treatment Satisfaction Questionnaire for Medication and 36-item
Short-Form Health Survey were completed at baseline and four visits to
assess patient satisfaction and quality of life.
Results: Forty-two patients (62\% male; mean age: 35.7 +/- 9.4 years)
were eligible for inclusion. Patient satisfaction scores at the end of
the study 44.7 +/- 9.9) were significantly higher than those at baseline
{[}32.0 +/- 9.9; (p<0.001)]. The only significant increase in the
quality of life survey was in the emotional aspect (p=0.019). There were
124 adverse events and none of the five serious adverse events noted was
considered drugrelated.
Conclusion: Large-scale comparative studies performed with disease
specific quality of life instruments will allow more information on this
issue
Demographics of patients with heart failure who were over 80 years old and were admitted to the cardiology clinics in Turkey
WOS: 000468584300005PubMed ID: 30930455Objective: Heart failure (HF) has a high prevalence and mortality rate in elderly patients; however, there are few studies that have focused on patients older than 80 years. The aim of this study is to describe and compare the age-specific demographics and clinical features of Turkish elderly patients with HF who were admitted to cardiology clinics. Methods: The Epidemiology of Cardiovascular Disease in Elderly Turkish population (ELDER-TURK) study was conducted in 73 centers in Turkey, and it recruited a total of 5694 patients aged 65 years or older. In this study, the clinical profile of the patients who were aged 80 years or older and those between 65 and 79 years with HF were described and compared based on the ejection fraction (EF)-related classification: HFrEF and HFpEF (is considered as EF: >= 50%). Results: A total of 1098 patients (male, 47.5%; mean age, 83.5 +/- 3.1 years) aged 80 years and 4596 patients (male, 50.2 %; mean age, 71.1 +/- 4.31 years) aged 65-79 years were enrolled in this study. The prevalence of HF was 39.8% for patients who were >= 80 years and 27.1% for patients 65-79 years old. For patients aged >= 80 years with HF, the prevalence rate was 67% for hypertension (HT), 25.6% for diabetes mellitus (DM), 54.3% for coronary artery disease (CAD), and 42.3% for atrial fibrilation. Female proportion was lower in the HFrEF group (p=0.019). The prevalence of HT and DM was higher in the HFpEF group (p= 80 years with HFrEF (p<0.01). Conclusion: HF is common in elderly Turkish population, and its frequency increases significantly with age. Females, diabetics, and hypertensives are more likely to have HFpEF, whereas CAD patients are more likely to have HFrEF.Turkish Society of CardiologyThis study was supported by Turkish Society of Cardiology
Demographics of patients with heart failure who were over 80 years old and were admitted to the cardiology clinics in Turkey
Objective: Heart failure (HF) has a high prevalence and mortality rate
in elderly patients; however, there are few studies that have focused on
patients older than 80 years. The aim of this study is to describe and
compare the age-specific demographics and clinical features of Turkish
elderly patients with HF who were admitted to cardiology clinics.
Methods: The Epidemiology of Cardiovascular Disease in Elderly Turkish
population (ELDER-TURK) study was conducted in 73 centers in Turkey, and
it recruited a total of 5694 patients aged 65 years or older. In this
study, the clinical profile of the patients who were aged 80 years or
older and those between 65 and 79 years with HF were described and
compared based on the ejection fraction (EF)-related classification:
HFrEF and HFpEF (is considered as EF: >= 50\%).
Results: A total of 1098 patients (male, 47.5\%; mean age, 83.5 +/- 3.1
years) aged 80 years and 4596 patients (male, 50.2 \%; mean age, 71.1
+/- 4.31 years) aged 65-79 years were enrolled in this study. The
prevalence of HF was 39.8\% for patients who were >= 80 years and 27.1\%
for patients 65-79 years old. For patients aged >= 80 years with HF, the
prevalence rate was 67\% for hypertension (HT), 25.6\% for diabetes
mellitus (DM), 54.3\% for coronary artery disease (CAD), and 42.3\% for
atrial fibrilation. Female proportion was lower in the HFrEF group
(p=0.019). The prevalence of HT and DM was higher in the HFpEF group
(p<0.01), whereas CAD had a higher prevalence in the HFrEF group
(p=0.02). Among patients aged 65-79 years, 43.9\% (548) had HFpEF, and
56.1\% (700) had HFrEF. In this group of patients aged 65-79 years with
HFrEF, the prevalence of DM was significantly higher than in patients
aged >= 80 years with HFrEF (p<0.01).
Conclusion: HF is common in elderly Turkish population, and its
frequency increases significantly with age. Females, diabetics, and
hypertensives are more likely to have HFpEF, whereas CAD patients are
more likely to have HFrEF